Frequently Asked Questions

Retatrutide is a new experimental medication from the GLP-1/GIP/Glucagon agonist class, developed for the treatment of obesity and type 2 diabetes. It works by reducing appetite, slowing stomach emptying, and affecting hormones that regulate metabolism and body weight.

TRIUMPH-4 Phase 3 trial showed participants lost up to 28.7% of their body weight over 68 weeks at the 12mg dose. This translates to approximately 72 pounds for someone starting at 250 pounds. Results depend on dosage, diet, and exercise adherence.

Retatrutide is primarily being developed for obesity treatment, with TRIUMPH trials focusing on weight loss in people with and without diabetes. It also significantly improves blood sugar control, reducing HbA1c by approximately 2% in diabetic patients, making it beneficial for both conditions.

FDA approval is expected in late 2027 or early 2028, with commercial launch following 1-3 months later. Eli Lilly must complete all seven TRIUMPH Phase 3 trials and submit a New Drug Application before the FDA's 10-month review process begins. Realistic availability: Q1-Q2 2028.

Long-term sustainability depends on continued medication use and lifestyle changes. Semaglutide and Tirzepatide have proven multi-year maintenance data. Retatrutide shows promise but lacks long-term studies beyond 68 weeks. All three require indefinite use—stopping treatment leads to weight regain within 2-3 weeks as appetite returns.

Yes. While Retatrutide, Semaglutide, and Tirzepatide can significantly reduce appetite and improve metabolism, combining them with a balanced diet, physical activity, and healthy routines maximizes results. Lifestyle changes also help sustain weight loss if the medication is discontinued.

Retatrutide is a triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors, while Semaglutide (Ozempic/Wegovy) only targets GLP-1. This triple mechanism produces 28.7% weight loss in trials compared to Semaglutide's 15%, nearly double the efficacy. The glucagon component enhances fat metabolism and energy expenditure.

Retatrutide activates three receptors (GLP-1, GIP, and glucagon), while Tirzepatide (Mounjaro/Zepbound) targets two (GLP-1 and GIP). In trials, Retatrutide produced 28.7% weight loss compared to Tirzepatide's 22.5%. The added glucagon component enhances fat burning and metabolic rate, creating superior weight loss results.

Clinical trials show Retatrutide achieves 28.7% weight loss at 68 weeks (TRIUMPH-4 data), while Tirzepatide produces 22.5% weight loss at 72 weeks (SURMOUNT-1). Retatrutide's triple-hormone mechanism provides approximately 6 percentage points more weight loss, making it the most effective obesity medication to date.

Retatrutide is a triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors, while Semaglutide (Ozempic/Wegovy) only targets GLP-1. This triple mechanism produces 28.7% weight loss in trials compared to Semaglutide's 15%, nearly double the efficacy. The glucagon component enhances fat metabolism and energy expenditure.

Retatrutide activates three receptors (GLP-1, GIP, and glucagon), while Tirzepatide (Mounjaro/Zepbound) targets two (GLP-1 and GIP). In trials, Retatrutide produced 28.7% weight loss compared to Tirzepatide's 22.5%. The added glucagon component enhances fat burning and metabolic rate, creating superior weight loss results.

Clinical trials show Retatrutide achieves 28.7% weight loss at 68 weeks (TRIUMPH-4 data), while Tirzepatide produces 22.5% weight loss at 72 weeks (SURMOUNT-1). Retatrutide's triple-hormone mechanism provides approximately 6 percentage points more weight loss, making it the most effective obesity medication to date.